Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clgc.2024.102182 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Androgen receptor pathway inhibitors vs. docetaxel chemotherapy for metastatic hormone-sensitive and first-line castration resistant prostate cancer.
World J Urol
December 2024
Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
Purpose: No currently available phase III trial compared docetaxel vs. androgen receptor pathway inhibitors (ARPI) regarding cancer-control outcomes in metastatic hormone-sensitive prostate cancer (mHSPC). Moreover, few is known about the effect of sequential therapies in mHSPC and subsequent metastatic castration resistant prostate cancer (mCRPC).
View Article and Find Full Text PDFAndrogen receptor and osteoglycin gene expression predicting prognosis of metastatic prostate cancer.
Sci Rep
December 2024
Department of Urology, Jichi Medical University, 3311-1 Yakushiji Shimotsuke, Tochigi, 329-0498, Japan.
This study aimed to identify the predictive factors associated with the oncological outcomes of metastatic hormone-sensitive prostate cancer-related genes. A nomogram for predicting prostate cancer-specific survival (CSS) was constructed based on biopsy samples obtained from 103 patients with metastatic hormone-sensitive prostate cancer. We analyzed the association between clinical data and mRNA expression levels.
View Article and Find Full Text PDFAlkaptonuria: a rare disease with multiorgan manifestation and a long-awaited diagnosis.
BMJ Case Rep
December 2024
Lungemedicinsk, Vejle Sygehus, Vejle, Denmark.
Alkaptonuria is a rare inherited disease resulting from a genetic variant leading to homogentisic acid accumulation in body tissues, causing a broad spectrum of symptoms. Our case involves a Caucasian male diagnosed in his 70s, who shares a constellation of symptoms and the diagnosis with his monozygotic twin brother. The symptoms include early-onset arthropathy, tendinopathy, osteopenia, discolouration of the auricular regions and fingers, scleral discolouration, secondary glaucoma, proteinuria, calcification of the mitral valve and black urethral and prostate stones.
View Article and Find Full Text PDFEighty-Nine Cases of Primary Prostatic Signet Ring Cell Carcinoma-Systematic Review.
Clin Genitourin Cancer
November 2024
Department of Urology, Wagga Wagga Base Hospital, Wagga Wagga, New South Wales, Australia; Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.
Signet ring cell adenocarcinoma is a rare subtype of mucinous adenocarcinoma that affects the gastrointestinal tract and the prostate. Prostatic signet ring cell carcinoma comprises 0.02% of all cases of prostate cancer and 0.
View Article and Find Full Text PDFPercutaneous Magnetic Resonance Imaging-Guided Focal Laser Ablation (MRI-FLA) of Prostate Tumors: A Systematic Review and Network Meta-Analysis.
J Pers Med
December 2024
Centre Hospitalier Universitaire de Bordeaux, Service de Radiologie et Imagerie Médicale de l'adulte, Place Amélie Raba Léon, 33076 Bordeaux, France.
MRI-guided focal laser ablation (MRI-FLA) is an emerging minimally invasive technique for treating localized prostate tumors, aiming to provide effective cancer control while minimizing side effects. This meta-analysis systematically evaluates the clinical outcomes, technical efficacy, and complication rates associated with MRI-FLA to better understand its therapeutic potential and safety profile in prostate cancer management. In July 2024, PubMed (MEDLINE) was searched for eligible trials using the PRISMA guidelines.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!